- Home
- NUVL vs WH Comparison
NUVL vs WH Comparison
Compare NUVL & WH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- WH
- Stock Information
- Founded
- NUVL 2017
- WH 2017
- Country
- NUVL United States
- WH United States
- Employees
- NUVL N/A
- WH N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- WH Hotels/Resorts
- Sector
- NUVL Health Care
- WH Consumer Discretionary
- Exchange
- NUVL Nasdaq
- WH Nasdaq
- Market Cap
- NUVL 5.8B
- WH 6.8B
- IPO Year
- NUVL 2021
- WH N/A
- Fundamental
- Price
- NUVL $81.76
- WH $86.08
- Analyst Decision
- NUVL Strong Buy
- WH Strong Buy
- Analyst Count
- NUVL 11
- WH 11
- Target Price
- NUVL $120.91
- WH $105.16
- AVG Volume (30 Days)
- NUVL 429.4K
- WH 755.7K
- Earning Date
- NUVL 08-07-2025
- WH 10-22-2025
- Dividend Yield
- NUVL N/A
- WH 1.91%
- EPS Growth
- NUVL N/A
- WH 38.05
- EPS
- NUVL N/A
- WH 4.27
- Revenue
- NUVL N/A
- WH $1,448,000,000.00
- Revenue This Year
- NUVL N/A
- WH $7.83
- Revenue Next Year
- NUVL N/A
- WH $5.94
- P/E Ratio
- NUVL N/A
- WH $20.16
- Revenue Growth
- NUVL N/A
- WH 4.32
- 52 Week Low
- NUVL $55.54
- WH $75.91
- 52 Week High
- NUVL $113.51
- WH $113.07
- Technical
- Relative Strength Index (RSI)
- NUVL 64.02
- WH 46.92
- Support Level
- NUVL $73.28
- WH $85.10
- Resistance Level
- NUVL $81.10
- WH $88.27
- Average True Range (ATR)
- NUVL 2.51
- WH 1.76
- MACD
- NUVL 0.84
- WH -0.25
- Stochastic Oscillator
- NUVL 92.63
- WH 21.69
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About WH Wyndham Hotels & Resorts Inc.
As of Dec. 31, 2024, Wyndham Hotels & Resorts operates 903,000 rooms across more than 20 brands predominantly in the economy and midscale segments. Super 8 is the largest brand, representing around 18% of all rooms, with Days Inn (13%) and Ramada (14%) the next two largest brands. During the past several years, the company has expanded its extended stay/lifestyle brands, which appeal to travelers seeking to experience the local culture of a given location. The company closed its La Quinta acquisition in the second quarter of 2018, adding around 90,000 rooms at the time the deal closed. Wyndham launched a new extended stay economy scale segment concept, ECHO, in the spring of 2022. The United States represents 56% of total rooms.